The U.S. Biosimilars Market will gain momentum from the increasing government support to adopt biosimilars in the healthcare sectors. According to a report by Fortune Business Insights, titled, “Biosimilars: U.S. Market Analysis, Insights and Forecast, 2019-2026,” The U.S. Biosimilars Market is projected to reach US$ 17,696.0 Mn by 2026. The report provides valuable insights into the drivers influencing growth of the market. As per the report, The U.S. Biosimilars Market is anticipated to report an impressive CAGR of 54.7% during the forecast period. The report also states that the U.S. market was valued at US$ 436.1 Mn in 2018.
Autoimmune Diseases Segment Projected to Dominate the Market in the U.S.
The U.S. biosimilars market is classified into three segments, namely, by distribution channel, by disease indication, and by drug class. By distribution channel, the market is grouped into online pharmacy, hospital pharmacy, and retail pharmacy. In terms of disease indication, the market is divided into cancer and autoimmune diseases such as arthritis, neutropenia, psoriasis, and others. In 2018, the autoimmune diseases held a market share of 92.0%.
The segment is anticipated to remain in the leading position the U.S. biosimilars market during the forecast period. Factors like increasing adoption of biosimilars, rise in the prevalence of autoimmune diseases, and availability of limited drugs are likely to boost the segment. The Centers of Disease Control and Prevention declared that approximately 26% adults are estimated to have arthritis by 2040. This in turn, will increase the demand for biosimilars to treat arthritis.
Moreover, treatment of cancer is expensive in the U.S. Combined with this, constant investments in research and development and rise in the adoption of sedentary lifestyle are projected to favor growth of the cancer segment throughout the forecast period in the U.S.
Some of the other players operating in the U.S. biosimilars market are
- Hoffmann-La Roche Ltd.,
- AbbVie Inc.,
- Merck & Co.,
- Celltrion Inc.,
- Coherus BioSciences, Inc.,
- Teva Pharmaceutical Industries Ltd.,
- Eli Lilly and Company
Get PDF Brochure of this Report@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/u-s-biosimilars-market-100990
Table of content:
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Prevalence of Key Disease Associated with the Scope – U.S., 2018
4.2 New Product Launch
4.3 Pipeline Analysis
4.4 Regulatory Scenario
4.5. Reimbursement Scenario
4.6. Patent Snapshot of Biologics
4.6 Key Industry Developments – Partnerships, Mergers & Acquisitions
5. U.S. Biosimilars Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Drug Class
5.2.1 Filgrastim & Pegfilgrastim
5.2.2 Monoclonal Antibodies
5.3. Market Analysis, Insights and Forecast – By Disease Indication
5.3.2 Autoimmune Diseases
5.4. Market Analysis, Insights and Forecast – By Distribution Channel
5.4.1 Hospital Pharmacy
5.4.2 Retail Pharmacy
5.4.3 Online Pharmacy
6. Competitive Analysis
6.1. Key Industry Developments
6.2. U.S. Market Share Analysis (2018)
6.3. Competition Dashboard
6.4. Comparative Analysis – Major Players
6.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
6.5.1 Novartis AG
6.5.2 Pfizer Inc.
6.5.3 Coherus BioSciences, Inc.
6.5.4 Teva Pharmaceutical Industries Ltd.
6.5.5 Merck & Co., Inc.
6.5.6 AbbVie Inc.
6.5.7 F. Hoffmann-La Roche Ltd.
6.5.8 Eli Lilly and Company
6.5.9 Celltrion Inc.
6.5.10 Amgen Inc.
6.5.11 Other Prominent Players
Order Full Report@ https://www.fortunebusinessinsights.com/checkout-page/100990
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.